Related Experiment Video
Updated: Feb 15, 2026

Reduced Itraconazole Concentration and Durations Are Successful in Treating Batrachochytrium dendrobatidis Infection in Amphibians
Published on: March 14, 2014
Simultaneous determination of voriconazole, posaconazole, itraconazole and hydroxy-itraconazole in human plasma using
Nicole Jenkins1, Marion Black1, Hans G Schneider2
1Clinical Biochemistry Unit, Alfred Pathology Service, Melbourne, Australia.
Introduction:
Invasive fungal infections are an increasing cause of mortality and morbidity in high risk patient populations such as those on immunosuppressive therapy. Triazole antifungals are recommended for the prevention and treatment of such infections. The aim of this study was to develop and validate a simple, sensitive and robust LCMS/MS method for the simultaneous analysis in human plasma of three frequently used antifungal drugs: voriconazole, posaconazole, and itraconazole.
Methods:
Precipitation reagent, containing deuterated internal standards, is added to 50μL of plasma. The vials are vortexed before centrifugation. The organic supernatant is transferred to a polypropylene vial and 1μL is injected into the Waters Acquity® Ultra Performance Liquid Chromatography system coupled with a Waters Acquity® TQ Detector system. Chromatographic separation is achieved on a BEH C18 column using gradient elution with mobile phases consisting of 2mM ammonium acetate with 0.1% formic acid in water and methanol. Run time is <5min between injections.
Results:
The evaluation of the LCMS/MS triazole method showed good precision (intra-assay CVs<6.7%, inter-assay CVs<8.3%). The lower limit of quantitation for all antifungal triazoles tested was 0.10mg/L. Passing Bablok comparisons of voriconazole (n=50) and posaconazole (n=50) showed good correlation with the current HPLC method (Voriconazole LCMS=0.94(HPLC)+0.03, r2=0.99; Posaconazole LCMS=1.18(HPLC)-0.04, r2=0.95). Passing Bablok comparisons of itraconazole and hydroxy-itraconazole (n=18) showed good agreement with an external referral laboratory's antifungal LCMS/MS method (Itraconazole LCMS=1.00(referral lab)+0.01, r2=0.99; Hydroxy-Itraconazole LCMS=1.05(referral lab)+0.04, r2=0.99). External quality assurance samples for posaconazole and voriconazole (n=12, UK NEQAS Antifungal Pilot Panel) were assayed 'blind' and results were in good agreement with consensus mean values (both r2=0.99).
Conclusion:
The rapid pre-analytical sample preparation procedure, short chromatographic time, limit of quantitation and linear range make this LCMS/MS method suitable for determination of plasma voriconazole, posaconazole, itraconazole and hydroxy-itraconazole levels in a high throughput laboratory.
Insights
A new LC-MS/MS method accurately measures voriconazole, posaconazole, and itraconazole in plasma. This rapid and sensitive assay is suitable for high-throughput clinical laboratories managing invasive fungal infections.
Area of Science:
- Analytical Chemistry
- Clinical Chemistry
- Pharmacology
Background:
- Invasive fungal infections (IFIs) pose a significant threat to immunocompromised patients.
- Triazole antifungals are crucial for IFI prevention and treatment.
- Accurate therapeutic drug monitoring is essential for optimizing patient outcomes.
Purpose of the Study:
- To develop and validate a sensitive, robust, and rapid LC-MS/MS method for simultaneous quantification of voriconazole, posaconazole, and itraconazole in human plasma.
- To establish a method suitable for routine clinical use in high-risk patient populations.
Main Methods:
- Plasma samples (50μL) underwent protein precipitation with deuterated internal standards.
- Analysis was performed using Ultra Performance Liquid Chromatography (UPLC) coupled with tandem mass spectrometry (MS/MS).
- Chromatographic separation was achieved on a C18 column with a run time under 5 minutes.
Main Results:
- The LC-MS/MS method demonstrated excellent precision (intra-assay CVs < 6.7%, inter-assay CVs < 8.3%).
- The lower limit of quantification for all tested triazoles was 0.10 mg/L.
- The method showed high correlation with existing HPLC and referral LC-MS/MS methods, confirmed by Passing Bablok regression and external quality assurance.
Conclusions:
- The developed LC-MS/MS method offers a rapid and reliable approach for quantifying key antifungal triazoles in plasma.
- Its efficiency, sensitivity, and accuracy make it ideal for high-throughput clinical laboratories.
- This method supports optimized therapeutic drug monitoring for patients at risk of invasive fungal infections.
Related Concept Videos
Composition of Blood Plasma
α-Hydroxy Ketones via Reductive Coupling of Esters: Acyloin Condensation Overview
Determining Order of Reaction
Determination
Enlargement of the Plasma Membrane
Plasma Membrane in Bacteria and Archaea

